Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Mar;69(3):473–481. doi: 10.1038/bjc.1994.86

Effects of photodynamic therapy on xenografts of human mesothelioma and rat mammary carcinoma in nude mice.

S L Gibson 1, T H Foster 1, R H Feins 1, R F Raubertas 1, M A Fallon 1, R Hilf 1
PMCID: PMC1968871  PMID: 8123476

Abstract

We have examined the effectiveness of photodynamic therapy against R3230AC rat mammary adenocarcinoma and human mesothelioma as xenografts in the same host. The results demonstrate that the xenografted human tumour is significantly more responsive to photodynamic treatment than the rodent mammary tumour. Studies also showed that the mesothelioma xenograft was fluence rate- and fluence-dependent while the rat tumour exposed to the same conditions demonstrated neither of these dependencies. This disparity in response was not attributable to a difference in either whole-tumour uptake or subcellular distribution of the porphyrin photosensitiser. Analysis of the effects of visible irradiation on cytochrome c oxidase activity, measured in mitochondria prepared from tumours borne on hosts injected with photosensitiser, demonstrated that photoradiation-induced enzyme inhibition was significantly greater in mesothelioma than in R3230AC mammary tumour preparations. However, in parallel studies conducted in vitro, when photosensitiser and light were delivered to previously unperturbed mitochondria, rates of enzyme inhibition were not significantly different. Both tumours were established in long-term cell culture. While the uptake of porphyrin photosensitiser was equivalent in both cell lines, the R3230AC cells displayed a significantly greater photosensitivity than the mesothelioma cells. The data presented here demonstrate that the mechanisms that govern response to photodynamic therapy are complex, but in the case of these two xenografted tumours host response to therapy is not likely to play a significant role.

Full text

PDF
473

Images in this article

479Figure 7
on p.479
479Figure 8
on p.479

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts A. S., Falkson G., Goedhals L., Vorobiof D. A., Van der Merwe C. A. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol. 1988 Mar;6(3):527–535. doi: 10.1200/JCO.1988.6.3.527. [DOI] [PubMed] [Google Scholar]
  2. Berg K., Moan J. Photodynamic effects of Photofrin II on cell division in human NHIK 3025 cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1988 May;53(5):797–811. doi: 10.1080/09553008814551141. [DOI] [PubMed] [Google Scholar]
  3. Canti G., Franco P., Marelli O., Ricci L., Nicolin A. Hematoporphyrin derivative rescue from toxicity caused by chemotherapy or radiation in a murine leukemia model (L1210). Cancer Res. 1984 Apr;44(4):1551–1556. [PubMed] [Google Scholar]
  4. Dougherty T. J., Mang T. S. Characterization of intra-tumoral porphyrin following injection of hematoporphyrin derivative or its purified component. Photochem Photobiol. 1987 Jul;46(1):67–70. doi: 10.1111/j.1751-1097.1987.tb04737.x. [DOI] [PubMed] [Google Scholar]
  5. Feins R. H., Hilf R., Ross H., Gibson S. L. Photodynamic therapy for human malignant mesothelioma in the nude mouse. J Surg Res. 1990 Oct;49(4):311–314. doi: 10.1016/0022-4804(90)90027-y. [DOI] [PubMed] [Google Scholar]
  6. Foster T. H., Gao L. Dosimetry in photodynamic therapy: oxygen and the critical importance of capillary density. Radiat Res. 1992 Jun;130(3):379–383. doi: 10.2307/3578385. [DOI] [PubMed] [Google Scholar]
  7. Foster T. H., Murant R. S., Bryant R. G., Knox R. S., Gibson S. L., Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 1991 Jun;126(3):296–303. doi: 10.2307/3577919. [DOI] [PubMed] [Google Scholar]
  8. Gibson S. L., Cohen H. J., Hilf R. Evidence against the production of superoxide by photoirradiation of hematoporphyrin derivative. Photochem Photobiol. 1984 Oct;40(4):441–448. doi: 10.1111/j.1751-1097.1984.tb04615.x. [DOI] [PubMed] [Google Scholar]
  9. Gibson S. L., Hilf R. Photosensitization of mitochondrial cytochrome c oxidase by hematoporphyrin derivative and related porphyrins in vitro and in vivo. Cancer Res. 1983 Sep;43(9):4191–4197. [PubMed] [Google Scholar]
  10. Gibson S. L., VanDerMeid K. R., Murant R. S., Raubertas R. F., Hilf R. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res. 1990 Nov 15;50(22):7236–7241. [PubMed] [Google Scholar]
  11. Gomer C. J., Dougherty T. J. Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res. 1979 Jan;39(1):146–151. [PubMed] [Google Scholar]
  12. Henderson B. W., Waldow S. M., Mang T. S., Potter W. R., Malone P. B., Dougherty T. J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res. 1985 Feb;45(2):572–576. [PubMed] [Google Scholar]
  13. Hilf R., Gibson S. L., Penney D. P., Ceckler T. L., Bryant R. G. Early biochemical responses to photodynamic therapy monitored by NMR spectroscopy. Photochem Photobiol. 1987 Nov;46(5):809–817. doi: 10.1111/j.1751-1097.1987.tb04852.x. [DOI] [PubMed] [Google Scholar]
  14. Hilf R., Murant R. S., Narayanan U., Gibson S. L. Relationship of mitochondrial function and cellular adenosine triphosphate levels to hematoporphyrin derivative-induced photosensitization in R3230AC mammary tumors. Cancer Res. 1986 Jan;46(1):211–217. [PubMed] [Google Scholar]
  15. Hissin P. J., Hilf R. Effects of insulin in vivo and in vitro on amino acid transport into cells from the R3230AC mammary adenocarcinoma and their relationship to tumor growth. Cancer Res. 1978 Nov;38(11 Pt 1):3646–3655. [PubMed] [Google Scholar]
  16. Keene J. P., Kessel D., Land E. J., Redmond R. W., Truscott T. G. Direct detection of singlet oxygen sensitized by haematoporphyrin and related compounds. Photochem Photobiol. 1986 Feb;43(2):117–120. doi: 10.1111/j.1751-1097.1986.tb09501.x. [DOI] [PubMed] [Google Scholar]
  17. Keller S. M., Taylor D. D., Weese J. L. In vitro killing of human malignant mesothelioma by photodynamic therapy. J Surg Res. 1990 Apr;48(4):337–340. doi: 10.1016/0022-4804(90)90070-i. [DOI] [PubMed] [Google Scholar]
  18. Kessel D., Cheng M. L. On the preparation and properties of dihematoporphyrin ether, the tumor-localizing component of HPD. Photochem Photobiol. 1985 Mar;41(3):277–282. doi: 10.1111/j.1751-1097.1985.tb03485.x. [DOI] [PubMed] [Google Scholar]
  19. Krarup-Hansen A., Hansen H. H. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol. 1991;28(5):319–330. doi: 10.1007/BF00685684. [DOI] [PubMed] [Google Scholar]
  20. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  21. Law M. R., Gregor A., Hodson M. E., Bloom H. J., Turner-Warwick M. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax. 1984 Apr;39(4):255–259. doi: 10.1136/thx.39.4.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. McDonald A. D., McDonald J. C. Malignant mesothelioma in North America. Cancer. 1980 Oct 1;46(7):1650–1656. doi: 10.1002/1097-0142(19801001)46:7<1650::aid-cncr2820460726>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  23. Moan J., Christensen T., Sommer S. The main photosensitizing components of hematoporphyrin derivative. Cancer Lett. 1982 Feb;15(2):161–166. doi: 10.1016/0304-3835(82)90046-5. [DOI] [PubMed] [Google Scholar]
  24. Muscat J. E., Wynder E. L. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res. 1991 May 1;51(9):2263–2267. [PubMed] [Google Scholar]
  25. Nahabedian M. Y., Cohen R. A., Contino M. F., Terem T. M., Wright W. H., Berns M. W., Wile A. G. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst. 1988 Jul 20;80(10):739–743. doi: 10.1093/jnci/80.10.739. [DOI] [PubMed] [Google Scholar]
  26. Perry R. R., Matthews W., Mitchell J. B., Russo A., Evans S., Pass H. I. Sensitivity of different human lung cancer histologies to photodynamic therapy. Cancer Res. 1990 Jul 15;50(14):4272–4276. [PubMed] [Google Scholar]
  27. Ris H. B., Altermatt H. J., Inderbitzi R., Hess R., Nachbur B., Stewart J. C., Wang Q., Lim C. K., Bonnett R., Berenbaum M. C. Photodynamic therapy with chlorins for diffuse malignant mesothelioma: initial clinical results. Br J Cancer. 1991 Dec;64(6):1116–1120. doi: 10.1038/bjc.1991.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Ris H. B., Altermatt H. J., Nachbur B., Stewart J. C., Wang Q., Lim C. K., Bonnett R., Althaus U. Effect of drug-light interval on photodynamic therapy with meta-tetrahydroxyphenylchlorin in malignant mesothelioma. Int J Cancer. 1993 Jan 2;53(1):141–146. doi: 10.1002/ijc.2910530126. [DOI] [PubMed] [Google Scholar]
  29. WAGNER J. C., SLEGGS C. A., MARCHAND P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960 Oct;17:260–271. doi: 10.1136/oem.17.4.260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Weishaupt K. R., Gomer C. J., Dougherty T. J. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res. 1976 Jul;36(7 Pt 1):2326–2329. [PubMed] [Google Scholar]
  31. Woodburn K. W., Stylli S., Hill J. S., Kaye A. H., Reiss J. A., Phillips D. R. Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy. Br J Cancer. 1992 Mar;65(3):321–328. doi: 10.1038/bjc.1992.66. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES